UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188-1194

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Annals of oncology, 2019-07, Vol.30, p.iv135-iv135

2019

Link zum Volltext

Verfügbarkeit prüfen

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

European journal of cancer (1990), 1999-11, Vol.35 (12), p.1688-1692

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer

Annals of oncology, 2003-10, Vol.14 (10), p.1543-1548

2003

Link zum Volltext

Verfügbarkeit prüfen

Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

Endocrine-related cancer, 2004-12, Vol.11 (4), p.771-779

2004

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women

Journal of clinical oncology, 2005-04, Vol.23 (10), p.2155-2161

2005

Link zum Volltext

Verfügbarkeit prüfen

Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism

Annals of oncology, 2002-07, Vol.13 (7), p.1059-1066

2002

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts): a pilot evaluation of toxicity. Preliminary results of the VICTOR-4 study

Annals of oncology, 2016-09, Vol.27, p.iv72

2016

Link zum Volltext

Verfügbarkeit prüfen

LBA36 - Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

Annals of oncology, 2019-10, Vol.30, p.v870-v870

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

Annals of oncology, 2019-10, Vol.30, p.v870

2019

Link zum Volltext

Verfügbarkeit prüfen

c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients

Breast (Edinburgh), 2002-08, Vol.11 (4), p.286-294

2002

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients

Endocrine-related cancer, 2004-12, Vol.11 (4), p.761-770

2004

Link zum Volltext

Verfügbarkeit prüfen

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188

2015

Link zum Volltext

Verfügbarkeit prüfen

Gefitinib (G) plus interleukin-2 (IL-2) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18042-18042

2007

Link zum Volltext

Verfügbarkeit prüfen

Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15068-15068

2007

Link zum Volltext

Verfügbarkeit prüfen

LBA36Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Link zum Volltext

Verfügbarkeit prüfen

Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy

Journal of biological regulators and homeostatic agents, 1998-01, Vol.12 (1-2), p.38

1998

Link zum Volltext

Verfügbarkeit prüfen

A dose finding study with erlotinib in combination to irinotecan and capecitabine in metastatic colorectal cancer (mCRC) patients

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13075-13075

2006

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed in gastric cancer: clinical experience and future perspectives

Seminars in oncology, 2002-12, Vol.29 (6 Suppl 18), p.63-68, Article asonc02906s0063

2002

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed in gastric cancer: Clinical experience and future perspectives

Seminars in oncology, 2002-12, Vol.29 (6), p.63-68

2002

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.8164-8164

2004

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.8164-8164

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(40)
Tagungsberichte
(1)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(16)
Female
(12)
Aged
(11)
Middle Aged
(11)
Oncology
(11)
Adult
(10)
Breast Neoplasms - Drug Therapy
(8)
Aged, 80 And Over
(7)
Treatment Outcome
(6)
Biological And Medical Sciences
(5)
Breast Neoplasms - Pathology
(5)
Endocrinology & Metabolism
(5)
Medical Sciences
(5)
Chemotherapy
(4)
Pharmacology. Drug Treatments
(4)
Postmenopause
(4)
Antimetabolites, Antineoplastic - Therapeutic Use
(3)
Antineoplastic Agents
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer

Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women

Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism

Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts): a pilot evaluation of toxicity. Preliminary results of the VICTOR-4 study

LBA36 - Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients

Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Gefitinib (G) plus interleukin-2 (IL-2) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study

LBA36Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA

O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy

LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study

A dose finding study with erlotinib in combination to irinotecan and capecitabine in metastatic colorectal cancer (mCRC) patients

Pemetrexed in gastric cancer: clinical experience and future perspectives

Pemetrexed in gastric cancer: Clinical experience and future perspectives

Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients

Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients

Suchergebnisse filtern